ArticleCureus2026
Clinical Outcomes of Stage IIIC Poor-Risk Testicular Germ Cell Tumors: A Retrospective Analysis From a Tertiary Care Center.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Testicular germ cell tumors (TGCTs) are the most common malignancy in young men. While highly chemosensitive with excellent cure rates in early stages, outcomes remain suboptimal in advanced disease. This study evaluated clinical outcomes of patients with stage IIIC poor-risk TGCTs, a subgroup with limited survival data. Methods A retrospective review was conducted of 31 consecutive patients with stage IIIC poor-risk TGCTs treated between May 2021 and November 2023 at a tertiary care center. Clinical, pathological, treatment, and outcome data were analyzed. Results Thirty-one patients with stage IIIC poor-risk non-seminomatous TGCTs were included. Six patients (19.4%) died during first-line chemotherapy. Among the 25 patients who completed therapy, nine (36.0%) developed relapse. Mean progression-free survival (PFS) was 32.3 months, and mean overall survival (OS) was 31.1 months. Patients achieving tumor marker normalization after chemotherapy had markedly superior outcomes (mean PFS: 41.8 vs. 10.0 months; mean OS: 36.3 vs. 19.1 months). Brain metastases at diagnosis or on progression were associated with poor prognosis. Conclusion Patients presenting with poor performance status and visceral crisis are at high risk of early mortality during first-line chemotherapy. Tumor marker normalization strongly predicts improved survival, whereas persistent marker elevation and brain metastases are linked to unfavorable outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.